The dent in sales is attributed to increasingly stiff competition in the interferon space as well as competition from oral forms and high-efficacy multiple sclerosis therapies, according to Merck KGaAs annual report
Copyright 2026 Nexstar Media, Inc
Why People Change The most common reasons are not clinical failure
No significant difference at all (not even a trend!) in motor scores between exenatide and placebo All the secondary endpoints were negative too
Para el anlisis, el sobrepeso y la obesidad se definieron segn las definiciones de IMC, as como los cdigos de diagnstico, y los criterios de inclusin exigan que esto se registrara al menos un ao antes de su fecha de ndice
(UCLA Health) In other words, if a GLP-1 helps you eat less, protein helps make sure less is still working for you and your metabolism